Palod Distributors-Home Page
Home Page About Us Products Group Companies Scheme Our Videos Contact Us
News Detail
Jan. 04 2014
Major Highlights for Month of November 2013:
November Month Highlights: Ø The IPM clocked 6291 Crs in November 2013 Ø The Indian Pharma Market grows at 6.9% for the month of November 2013 Ø Macleods becomes the 10th biggest company in IPM versus 11th of last month Ø Nov 13 Growth driver split shows positive on the parameter of Volume & New Introductions leadings to overall positive growths over Oct 12 Ø Corporates: Ø For the month of November 2013, amongst the top 10, Sun Pharma at 17.1% followed by Alkem* at 12.5% Ø 34 corporates have crossed the growth of IPM for the month of November 2013 amongst top 50 Ø Amongst the top 50 Corporates, Corona Remedies has the highest growth of 87.2% followed by Biocon at 49.6% & Ipca at 28.3% Ø Amongst the 11-20 ranked companies Glenmark shows high growth at 25.6% followed by Aristo* at 20.8% and USV at 20.6% Ø 29 out of top 50 Corporates have grown in double digits as compared to 13 corporates in Oct 2013 Ø Akumentis enters the 250 Crs Club, BMS enters the 100 Cr Club, Ø Indian V/S MNCs: Ø Indian companies have grown at 11.1% versus -5.1% for MNCs in Nov 2013 Ø Amongst the top 50 in MNCs AstraZeneca grew the highest at 20.0%, followed by Allergan at 16.5% & Merck at 12.1% Ø DPCO 2013 V/s Non DPCO 2013 Market: Ø The DPCO 2013 containing molecules market was at –8.6% whereas the non DPCO market grew by 9.5% resulting in an overall growth of 6.9% for November 2013 Ø The DPCO 2013 portfolio for GSK degrew at 31.8% & Ranbaxy degrew by 20.7%, whereas Sun Pharma had the least impact with its DPCO 2013 portfolio degrowing at 6.8% Ø The Unit Market grew positively after a long time
Dear All,
 
A Positive Evening to everyone from PharmaTrac
 
After 3 continuous months of Volume degrowths, the IPM market witnessed a seasonal change with once again the numbers coming to positive for the month of November 2013. The Price Growth component was at 0.8% thereby signifying the impact of price cuts witnessed due to the implementation of the pricing policy. However the volume growths that was seen in the last years is still far off.
 
 
Major Highlights for Month of November 2013:
 
Ø  November Month Highlights:
Ø  The IPM clocked 6291 Crs in November 2013
Ø  The Indian Pharma Market grows at  6.9% for the month of November 2013
Ø  Macleods becomes the 10th biggest company in IPM versus 11th of last month
Ø  Nov 13 Growth driver split shows positive on the parameter of Volume & New Introductions leadings to overall positive growths over Oct 12
 
Ø  Corporates:
Ø  For the month of November 2013, amongst the top 10, Sun Pharma at 17.1% followed by Alkem* at 12.5%
Ø  34 corporates have crossed the growth of IPM for the month of November 2013 amongst top 50
Ø  Amongst the top 50 Corporates, Corona Remedies has the highest growth of 87.2% followed by Biocon at 49.6% & Ipca at 28.3%
Ø  Amongst the 11-20 ranked companies Glenmark shows high growth at 25.6% followed by Aristo* at 20.8% and USV at 20.6%
Ø  29 out of top 50 Corporates have grown in double digits as compared to 13 corporates in Oct 2013
Ø  Akumentis enters the 250 Crs Club,  BMS enters the 100 Cr Club,
 
Ø  Indian V/S MNCs:
Ø  Indian companies have grown at 11.1% versus -5.1% for MNCs in Nov 2013
Ø  Amongst the top 50 in MNCs AstraZeneca grew the highest at 20.0%, followed by Allergan at 16.5% & Merck at 12.1%
 
Ø  DPCO 2013  V/s Non DPCO 2013 Market:
Ø  The DPCO 2013 containing molecules market was at –8.6% whereas the non DPCO market grew by 9.5% resulting in an overall growth of 6.9% for November 2013
Ø  The DPCO 2013  portfolio for GSK degrew at 31.8% & Ranbaxy degrew by 20.7%, whereas Sun Pharma had the least impact with its DPCO 2013 portfolio degrowing at 6.8%
Ø  The Unit Market grew positively after a long time
 
 
 
Ø  Therapy:
Ø  From therapy perspective 8 therapies have outgrown the IPM growth
Ø  Gastrointestinal Market grew at 8.4%, anti-infective market had a growth of 2.6% whereas respiratory market had a 15.1% growth
Ø  Anti-diabetic market grows at 6.1% & Cardiac at 7.2% in chronic business
Ø  Anti-malarials grew by 21.2%, whereas Derma market was at 15.2%
Ø  Bonus in the Anti-infective segment grew by 5.1%, whereas in Respiratory market it was 19.1% growth
 
Ø  Regional Dynamics:
Ø  From regional perspective 11 regions have outgrown the IPM growth
Ø  Bihar grows highest at 16.6%  whereas Delhi has registered 16.4%
Ø  Biggest Region Tamil Nadu degrew at 7.5% & AP Rest degrew at 5.2%
Ø  2 regions have had negative growths in Nov 13
 
Ø  Molecules:
Ø  The biggest molecule Amoxycillin + Clavulanic grew by 9.7%, whereas Cefixime grew at 2.3%.
Ø  Paracetamol grew at 5.1% & Azithromycin grew by 2.7%
Ø  The markets of Vitamin- D grew by 49.5%, Glimepiride + Metformin grew at 40.8%, Rosuvastain, Levocetirizine + Montelukast  & Telmisartan by 22.0%.
 
Ø  Brands:
Ø  Amongst the top brands in the IPM, Phensedyl shows 63% growth, Glycomet-GP shows 62% growth, Moxikind – CV at 33%, Clavam is at 29%
 
With Bonus Units at Full Value   Without Bonus Units
Rank MAT Nov -13 Nov-13 Val in Crs Rank MAT Nov-13 Nov-13
MAT MTH Val (Cr) MS% GR% Val (Cr) MS% GR% COMPANY MAT MTH Val (Cr) MS% GR% Val (Cr) MS% GR%
    72772 100.00 5.3 6291 100.00 6.9 IPM     69987 100.00 5.4 6041 100.00 6.8
1 1 3873 5.32 17.4 357 5.67 17.1 Sun Pharma 1 1 3800 5.43 16.7 348 5.75 15.7
2 2 3694 5.08 5.6 328 5.22 12.2 Cipla 2 2 3419 4.88 8.4 308 5.10 15.3
3 3 2987 4.10 13.7 262 4.16 9.9 Zydus Cadila 5 3 2810 4.01 14.1 245 4.06 9.5
4 4 2916 4.01 2.1 251 3.98 2.1 Ranbaxy 4 4 2822 4.03 2.2 242 4.01 2.4
5 7 2886 3.97 -10.5 221 3.51 -20.1 Glaxo 3 6 2833 4.05 -10.4 218 3.61 -19.3
6 5 2702 3.71 1.1 232 3.69 3.3 Abbott HC 6 5 2617 3.74 0.6 225 3.72 2.6
7 6 2627 3.61 6.8 232 3.68 10.4 Mankind 7 7 2208 3.15 9.7 194 3.21 12.9
8 8 2283 3.14 8.5 206 3.27 12.0 Alkem 9 8 2117 3.02 7.6 191 3.16 11.8
9 9 2197 3.02 6.6 195 3.09 9.9 Lupin 8 9 2149 3.07 6.3 190 3.14 8.8
10 10 1878 2.58 7.5 167 2.66 11.7 Macleods 11 11 1764 2.52 7.7 157 2.60 11.6
11 12 1853 2.55 12.9 160 2.54 12.0 Intas 10 10 1835 2.62 12.4 158 2.62 11.4
12 11 1736 2.39 7.2 166 2.63 20.8 Aristo 14 12 1545 2.21 5.5 146 2.42 17.8
13 16 1627 2.24 -1.3 124 1.97 -16.6 Pfizer 12 17 1595 2.28 -1.3 121 2.01 -16.7
14 14 1618 2.22 8.5 139 2.22 7.2 Dr. Reddys 13 14 1591 2.27 7.9 136 2.25 5.9
15 13 1543 2.12 15.0 146 2.31 25.6 Glenmark 15 13 1501 2.14 14.7 141 2.34 25.1
16 15 1419 1.95 3.6 125 1.98 10.7 Abbott 16 15 1411 2.02 3.4 124 2.05 10.3
17 22 1414 1.94 1.0 111 1.76 -6.8 Sanofi-Aventis 17 21 1401 2.00 0.6 110 1.81 -7.3
18 17 1368 1.88 15.8 122 1.95 20.6 USV 18 16 1361 1.94 15.8 122 2.02 20.5
19 20 1298 1.78 14.9 114 1.81 10.7 Torrent 19 18 1278 1.83 15.0 112 1.85 10.4
20 19 1290 1.77 2.9 114 1.82 9.4 Micro Lab 20 22 1231 1.76 2.6 109 1.81 9.6
21 18 1237 1.70 14.7 119 1.89 28.3 Ipca 22 19 1173 1.68 13.9 112 1.85 26.3
22 21 1210 1.66 16.2 114 1.81 29.0 Emcure 21 20 1185 1.69 16.5 112 1.85 29.4
23 23 1162 1.60 -3.6 107 1.70 8.8 Wockhardt 23 23 1139 1.63 -3.9 104 1.73 8.2
24 24 1150 1.58 2.4 98 1.55 -0.8 Novartis 24 24 1103 1.58 2.6 94 1.56 0.0
25 25 995 1.37 8.1 92 1.46 25.0 Alembic 25 25 961 1.37 8.1 89 1.47 25.3
26 27 842 1.16 14.9 67 1.07 5.5 Zuventus 26 27 803 1.15 15.0 64 1.06 5.3
27 26 798 1.10 0.7 69 1.09 7.9 FDC 27 26 776 1.11 0.7 67 1.11 7.9
28 28 727 1.00 3.4 60 0.96 0.9 Unichem 28 28 714 1.02 2.7 59 0.98 0.2
29 32 690 0.95 -7.7 48 0.77 -29.4 Novo Nordisk 29 31 689 0.98 -7.6 48 0.80 -29.5
30 40 608 0.84 -14.4 32 0.51 -47.6 Elder 30 41 574 0.82 -14.0 31 0.51 -45.7
31 29 589 0.81 11.1 52 0.83 27.2 Cadila 31 29 569 0.81
eXpert Solution by
North South Technologies Pvt. Ltd.